vs
阿斯利康（AZN）与JBS N.V.（JBS）财务数据对比。点击上方公司名可切换其他公司
JBS N.V.的季度营收约是阿斯利康的1.6倍（$22.6B vs $14.5B），阿斯利康净利率更高（16.9% vs 2.9%，领先14.1%），JBS N.V.同比增速更快（13.4% vs 11.7%）
阿斯利康是一家瑞典与英国合资的跨国制药及生物技术企业，总部位于英国剑桥的剑桥生物医学园区。公司产品管线覆盖肿瘤、心血管、消化、感染、神经科学、呼吸、炎症等重大疾病领域。
JBS N.V.是巴西跨国企业，为全球规模最大的肉类加工集团，生产工厂化加工的牛肉、鸡肉、三文鱼、羊肉、猪肉等产品，同时销售肉类加工衍生的各类副产品，总部设于圣保罗，1953年在戈亚斯州阿纳波利斯成立。
AZN vs JBS — 直观对比
营收规模更大
JBS
是对方的1.6倍
$14.5B
营收增速更快
JBS
高出1.7%
11.7%
净利率更高
AZN
高出14.1%
2.9%
损益表 — Q2 FY2025 vs Q3 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $14.5B | $22.6B |
| 净利润 | $2.4B | $644.1M |
| 毛利率 | 82.9% | 13.2% |
| 营业利润率 | 24.3% | 5.4% |
| 净利率 | 16.9% | 2.9% |
| 营收同比 | 11.7% | 13.4% |
| 净利润同比 | 27.0% | -14.9% |
| 每股收益（稀释后） | $1.57 | $0.52 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收AZNJBS
| Q3 25 | — | $22.6B | ||
| Q2 25 | $14.5B | — | ||
| Q3 24 | — | $19.9B | ||
| Q2 24 | $12.9B | — | ||
| Q2 23 | $11.4B | — | ||
| Q2 22 | $10.8B | — |
净利润AZNJBS
| Q3 25 | — | $644.1M | ||
| Q2 25 | $2.4B | — | ||
| Q3 24 | — | $756.6M | ||
| Q2 24 | $1.9B | — | ||
| Q2 23 | $1.8B | — | ||
| Q2 22 | $360.0M | — |
毛利率AZNJBS
| Q3 25 | — | 13.2% | ||
| Q2 25 | 82.9% | — | ||
| Q3 24 | — | 16.5% | ||
| Q2 24 | 83.1% | — | ||
| Q2 23 | 82.8% | — | ||
| Q2 22 | 72.2% | — |
营业利润率AZNJBS
| Q3 25 | — | 5.4% | ||
| Q2 25 | 24.3% | — | ||
| Q3 24 | — | 7.8% | ||
| Q2 24 | 21.2% | — | ||
| Q2 23 | 21.5% | — | ||
| Q2 22 | 5.0% | — |
净利率AZNJBS
| Q3 25 | — | 2.9% | ||
| Q2 25 | 16.9% | — | ||
| Q3 24 | — | 3.8% | ||
| Q2 24 | 14.9% | — | ||
| Q2 23 | 15.9% | — | ||
| Q2 22 | 3.3% | — |
每股收益（稀释后）AZNJBS
| Q3 25 | — | $0.52 | ||
| Q2 25 | $1.57 | — | ||
| Q3 24 | — | $0.62 | ||
| Q2 24 | $1.24 | — | ||
| Q2 23 | $1.17 | — | ||
| Q2 22 | $0.23 | — |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $7.1B | $485.5B |
| 总债务越低越好 | — | $213.0M |
| 股东权益账面价值 | $44.8B | $9.5B |
| 总资产 | $112.4B | $44.2B |
| 负债/权益比越低杠杆越低 | — | 0.02× |
8季度趋势，按日历期对齐
现金及短期投资AZNJBS
| Q3 25 | — | $485.5B | ||
| Q2 25 | $7.1B | — | ||
| Q3 24 | — | $5.1B | ||
| Q2 24 | $6.9B | — | ||
| Q2 23 | $5.7B | — | ||
| Q2 22 | $4.8B | — |
总债务AZNJBS
| Q3 25 | — | $213.0M | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
股东权益AZNJBS
| Q3 25 | — | $9.5B | ||
| Q2 25 | $44.8B | — | ||
| Q3 24 | — | $9.5B | ||
| Q2 24 | $39.6B | — | ||
| Q2 23 | $37.4B | — | ||
| Q2 22 | $36.0B | — |
总资产AZNJBS
| Q3 25 | — | $44.2B | ||
| Q2 25 | $112.4B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | $104.3B | — | ||
| Q2 23 | $96.5B | — | ||
| Q2 22 | $96.6B | — |
负债/权益比AZNJBS
| Q3 25 | — | 0.02× | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | — | $996.4M |
| 自由现金流经营现金流 - 资本支出 | — | $-264.6M |
| 自由现金流率自由现金流/营收 | — | -1.2% |
| 资本支出强度资本支出/营收 | — | 5.6% |
| 现金转化率经营现金流/净利润 | — | 1.55× |
| 过去12个月自由现金流最近4个季度 | — | — |
8季度趋势，按日历期对齐
经营现金流AZNJBS
| Q3 25 | — | $996.4M | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
自由现金流AZNJBS
| Q3 25 | — | $-264.6M | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
自由现金流率AZNJBS
| Q3 25 | — | -1.2% | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
资本支出强度AZNJBS
| Q3 25 | — | 5.6% | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
现金转化率AZNJBS
| Q3 25 | — | 1.55× | ||
| Q2 25 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q2 23 | — | — | ||
| Q2 22 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
